Agentix Corp. is a clinical-stage pharmaceutical company focused on developing peripherally-restricted cannabinoid type 1 (CB1) receptor antagonists to treat metabolic diseases including obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). Its two key pipeline assets, AGTX-2004 and AGTX-2003, are designed to not cross the blood-brain barrier. Development activities are conducted through its Australian subsidiary, Agentix Australia Pty Ltd, to leverage a 43.5% R&D tax rebate program.
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-07-16 | 2025-03-31 | 0001477932-25-005077 | EDGAR | 19K words |
| 2024-08-30 | 2024-03-31 | 0001477932-24-005401 | EDGAR | 20K words |
| 2023-07-14 | 2023-03-31 | 0001477932-23-005252 | EDGAR | 22K words |
| 2021-10-07 | 2021-08-31 | 0001477932-21-007074 | EDGAR | 23K words |
| 2020-12-09 | 2020-08-31 | 0001477932-20-007176 | EDGAR | 21K words |
| 2019-12-05 | 2019-08-31 | 0001477932-19-006966 | EDGAR | 23K words |
| 2018-11-13 | 2018-08-31 | 0001477932-18-005427 | EDGAR | 24K words |
| 2017-12-18 | 2017-08-31 | 0001477932-17-006133 | EDGAR | 25K words |
| 2016-12-12 | 2016-08-31 | 0001477932-16-014034 | EDGAR | 24K words |
| 2015-12-16 | 2015-08-31 | 0001477932-15-007657 | EDGAR | 23K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001477932-26-004781 | EDGAR | 9K words |
| 2026-02-17 | 2025-12-31 | 0001477932-26-000845 | EDGAR | 11K words |
| 2025-11-20 | 2025-09-30 | 0001477932-25-008502 | EDGAR | 10K words |
| 2025-08-22 | 2025-06-30 | 0001477932-25-006197 | EDGAR | 9K words |
| 2025-02-18 | 2024-12-31 | 0001477932-25-001090 | EDGAR | 11K words |
| 2024-11-18 | 2024-09-30 | 0001477932-24-007361 | EDGAR | 10K words |
| 2024-09-25 | 2024-06-30 | 0001477932-24-005905 | EDGAR | 9K words |
| 2024-02-14 | 2023-12-31 | 0001477932-24-000711 | EDGAR | 11K words |
| 2023-11-20 | 2023-09-30 | 0001477932-23-008660 | EDGAR | 10K words |
| 2023-08-22 | 2023-06-30 | 0001477932-23-006393 | EDGAR | 9K words |
| 2023-02-14 | 2022-12-31 | 0001477932-23-000969 | EDGAR | 11K words |
| 2022-11-14 | 2022-09-30 | 0001477932-22-008435 | EDGAR | 10K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2022-06-14 | 0001477932-22-004371 | EDGAR | 5K words |
| 2021-12-21 | 0001477932-21-009384 | EDGAR | 1K words |
| 2021-07-16 | 0001477932-21-004665 | EDGAR | 1K words |
| 2021-07-14 | 0001477932-21-004619 | EDGAR | 2K words |
| 2021-06-04 | 0001477932-21-003821 | EDGAR | 0K words |
| 2021-05-27 | 0001477932-21-003606 | EDGAR | 7K words |
| 2020-07-30 | 0001477932-20-004467 | EDGAR | 1K words |
| 2020-07-08 | 0001477932-20-003823 | EDGAR | 1K words |
| 2020-05-29 | 0001477932-20-003141 | EDGAR | 18K words |
| 2020-05-13 | 0001477932-20-002623 | EDGAR | 1K words |
70 total filings indexed. 38 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001603345 |
| Ticker | AGTX |
| Exchange | OTC |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | NV |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/AGTX (~200 tokens, structured JSON with cryptographic provenance)